Loading...
•
Sep 30, 2023
IRadimed Q3 2023 Earnings Report
IRADIMED CORPORATION reported record revenue and increased operating income for the third quarter of 2023.
Key Takeaways
IRADIMED CORPORATION announced record revenue of $16.5 million for the third quarter of 2023, representing a 23% year-over-year growth. The company's operating income increased by 43% compared to the same period in 2022, with GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.
Reported record revenue of $16.5 million for Q3 2023.
GAAP diluted EPS was $0.40 and non-GAAP diluted EPS was $0.43.
Operating income for Q3 2023 was $5.9 million, a 43% increase year-over-year.
Monitoring business led revenue growth, increasing 40% over Q2 2023.
Forward Guidance
For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38, and non-GAAP diluted earnings per share of $0.38 to $0.41. For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37, and non-GAAP diluted earnings per share of $1.48 to $1.51.
Positive Outlook
- Expects Q4 2023 revenue of $16.9 million to $17.4 million.
- Projects Q4 2023 GAAP diluted EPS of $0.35 to $0.38.
- Anticipates Q4 2023 non-GAAP diluted EPS of $0.38 to $0.41.
- Forecasts full-year 2023 revenue of $65.0 million to $65.5 million.
- Raises full-year 2023 GAAP diluted EPS guidance to $1.34 to $1.37.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...